Jubilant Pharmova Limited announced that its Board of Directors has approved the unaudited financial results for the quarter ended June 30, 2026. The results, which include both standalone and consolidated figures, were approved during a board meeting held on August 10, 2026. These financial statements have undergone a limited review by the statutory auditors and will be posted on the company’s website.
Board Approves Unaudited Financial Results
Jubilant Pharmova Limited confirmed on August 10, 2026, that its Board of Directors has officially approved the unaudited financial results for the quarter ended June 30, 2026. This significant board meeting, which convened from 05:30 p.m. to 07:05 p.m., concluded with the endorsement of the company’s financial performance for the first quarter of the fiscal year.
Standalone and Consolidated Performance
The approved results encompass both the standalone and consolidated financial statements. These results were prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting, and comply with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited financial results and the accompanying limited review report have been submitted to the stock exchanges and will be made available on the company’s official website, www.jubilantpharmova.com.
Key Financial Highlights (Quarter Ended June 30, 2026)
While detailed figures are available in the full report, the approved unaudited financial results for the quarter ended June 30, 2026, provide investors with critical insights into the company’s operational and financial health. The accompanying documents include:
- The unaudited Financial Results (Standalone and Consolidated).
- The Limited Review Report on these results.
The company has ensured that these documents are accessible to all stakeholders by simultaneously posting them on its website.
Source: BSE
